Outcome of female and male patients with DLBCL in the MInT study. Young good-prognosis (aaIPI = 0.1) male patients benefited at least as much as young good-prognosis females from the addition of rituximab. Upper row: females without rituximab (n = 189; gray curves) and females with rituximab (n = 156; black curves). Lower row: males without rituximab (n = 221; gray curves) and males with rituximab (n = 257; black curves). For multivariable analyses, see Table 1.